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Abstract
The aim of this case report is to describe control of Schamberg's disease using aminaphtone. We
report on the case of a 28-year-old patient who presented with multiple purpuric lesions of the
lower extremities which had appeared spontaneously. A biopsy of the skin was performed that
showed a perivascular T-cell lymphocytic infiltrate centered on the small superficial blood vessels
of the skin and so a diagnosis of Schamberg's disease was reached. The patient was prescribed
corticoids and the lesions disappeared however on suspension of the medication the lesions re-
emerged within three to seven days. This treatment was unsuccessfully continued for more than
one year. Thus another therapeutic option was attempted: 75 mg of aminaphtone was prescribed
twice daily for one month and the purpuric lesions disappeared within about one week. One year
after suspending the medication no relapse of the purpura was observed.
Introduction
Since progressive pigmented purpuric dermatitis, also
known as Schamberg's disease, was first described in
1901, several articles have appeared that have dealt largely
with clinical and histologic features of the illness[1]. The
lesions may occur in any location but most often affect the
lower extremities. The skin lesions are nonpalpable mac-
ules, which are typically asymptomatic, may persist for
months to years; normally only the aesthetic appearance
is of concern to patients [2].
Histologic examinations show a lymphocytic vasculitis
involving the blood vessels of the upper dermis with
endothelial swelling and extravasated red blood cells[3].
Several therapies have been used including topical and
systemic corticosteroids, vitamin C and topical and sys-
temic anti-inflammatory agents[4]. As aminaphtone has
been used to treat patients with changes in capillary per-
meability and fragility[5,6], it may be useful in the control
of Schamberg's disease. The aim of this case report is to
describe the treatment of Schamberg's disease using ami-
naphtone.
Case report
We report on the case of a 28-year-old patient who, at the
age of 24, presented with multiple purpuric lesions of the
lower extremities which appeared spontaneously (Figure
1). Biochemical examinations, a complete blood test and
coagulogram all gave normal results. A biopsy of the skin
was then performed that showed a perivascular T-cell lym-
phocytic infiltrate centered on the small superficial blood
vessels of the skin and so a diagnosis of Schamberg's dis-
ease was reached. The patient was prescribed corticoids
and the lesions disappeared however on suspension of the
medication the lesions re-emerged within three to seven
days. This treatment was unsuccessfully continued for
more than one year. Thus another therapeutic option was
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attempted: 75 mg of aminaphtone was prescribed twice
daily for one month and the purpuric lesions disappeared
within about one week. One year after suspending the
medication no relapse of the purpura was observed. This
study was approved by the Ethics Committee of Medical
School of São Jose do Rio Preto, Brazil (FAMERP).
Discussion
The current report describes the control of purpuric
lesions using aminaphtone for a young female patient
with Schamberg's disease. The etiology of this disease
remains relatively unknown and there is no consensus to
which medication is best for its control, perhaps due to
the scarcity of published case reports.
The use of aminaphtone in this disease aims at improving
capillary fragility and, in this case it successfully control-
led the purpuric lesions. The use of other medications,
such as pentoxifylline, corticoid and vitamin C, has also
been described. This new option seems to be attractive
due to the few side effects reported for the medication and
the long periods without the reappearance of the purpuric
lesions. However further studies are necessary to evaluate
its efficacy over the long term.
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Purpuric lesions on the lower extremities of the 28-year-old  female patient Figure 1
Purpuric lesions on the lower extremities of the 28-
year-old female patient.